This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Nov 2013

PSR-Agility Orphan Drug Development Wins ROAR Award for 'Best Orphan Drug CRO'

The PSR-Agility Orphan Drug Development partnership has been awarded 'Best Orphan Drug Contract Research Organisation' in the Rare & Orphan Advocacy and Research (ROAR) Awards.


The ROAR Awards were announced during the 4th Annual World Orphan Drug Congress Europe, 14–15 November 2013, in Geneva, Switzerland. The inaugural 2013 awards are an opportunity to recognise and honour achievements by organisations and individuals from industry, patient and rare disease advocacy communities.


“Winning this award as the PSR-Agility Orphan Drug Development partnership is an important acknowledgement for our pioneering work in the rare disease community during the last 5 years,” says Roger Legtenberg, CEO of PSR Orphan Experts. “As a unique specialised service provider, our way of integrating innovative regulatory and clinical approaches, and reaching crucial milestones for our clients has been the basis for winning this award. Our staff are all fully committed to the rare disease cause, taking part in fundraising events and other supportive activities.


“We established the PSR-Agility partnership so that our combined efforts in Europe and North America could make a difference for companies that are developing therapies for orphan products,” says Ellen Morgan, CEO of Agility.  “Winning this award is a great confirmation that our efforts are working, and has made us even more motivated to continue our efforts.”


Orphan drugs present fundamentally different regulatory and operational challenges compared to their traditional counterparts. PSR-Agility Orphan Drug Development specialises in assisting companies to develop efficiencies and economies of scale to bring innovative new orphan products to market, thereby helping patients with rare diseases. Building successful partnerships with all stakeholders, including patient organisations, industry and key opinion leaders is of crucial importance. This is exemplified by the DevelopAKUre consortium, of which PSR Orphan Experts is one of the partners, winning a ROAR Award of the 'Best European Industry–Patient Organisation Engagement'.

Related News